Why avoid live vaccines during Cosentyx treatment?
Cosentyx (secukinumab) suppresses the immune system by blocking interleukin-17A, increasing infection risk. Live vaccines contain weakened live viruses or bacteria that replicate in the body to trigger immunity. In immunocompromised patients, these can cause uncontrolled infection instead of protection.[1]
Guidelines recommend avoiding live vaccines during Cosentyx use and for varying periods afterward—typically until drug levels drop sufficiently (e.g., 4-6 months post-last dose, based on half-life of ~25-30 days).[2][3]
Which live vaccines are restricted?
Common examples include:
- MMR (measles, mumps, rubella)
- Varicella (chickenpox/shingles)
- Oral polio, rotavirus, and yellow fever
- Live nasal flu vaccine (FluMist)
Inactivated or recombinant vaccines (e.g., injectable flu, COVID-19 shots, HPV) are generally safe and encouraged.[1][4]
How long after stopping Cosentyx can you get live vaccines?
Wait at least 4 weeks after the last dose per Cosentyx prescribing information, but clinical experts often advise 3-6 months or longer. Timing depends on drug clearance, confirmed via blood tests if needed. Restarting Cosentyx requires 4 weeks post-vaccination.[2][5]
What if vaccination is urgent during treatment?
Consult a doctor. Non-live alternatives are preferred. For high-risk cases (e.g., travel), benefits may outweigh risks after specialist review—rarely approved without immunosuppression reversal.[3][6]
Does this apply to all IL-17 inhibitors?
Yes, similar warnings for ixekizumab (Taltz) and brodalumab (Siliq), as they share the IL-17 blockade mechanism.[4]
Patient risks and real-world data
Post-marketing reports show rare disseminated varicella or BCG infections in Cosentyx users. A 2022 review found no confirmed live vaccine transmissions but stressed avoidance due to theoretical risk.[5][7]
Sources:
[1] Cosentyx Prescribing Information (Novartis)
[2] FDA Label for Secukinumab
[3] CDC Guidelines on Immunization for Immunocompromised
[4] ACR Guidelines for Vaccinations in Rheumatic Diseases
[5] European Medicines Agency (EMA) SmPC for Cosentyx
[6] IDSA/ASID Vaccine Guidance
[7] PubMed Review: Secukinumab Safety (2022)